Bengü GİRENİZ TATAR, Sabri ATALAY, Melda TÜRKEN, Pelin ADAR, Gözde DERVİŞ HAKİM, Şükran KÖSE, Kamil MERT

HASTANEYE YATAN COVID-19 POZİTİF HASTALARDA HİDROKSİKLOROKİNİN ETKİNLİĞİ

Giriş: Bu çalışmada, Türkiye'deki referans hastanelerden biri olarak, COVİD-19 hastalarının tedavisinde Hidroksiklorokin’in (HCQ) etkinliği ve güvenliği ile ilgili gözlemlerimizi sunmayı amaçladık. Gereç ve Yöntem: Daha önce tedavi görmemiş 441 (13 Mart ve 15 Haziran 2020 arasında), hastanede yatan ve polimeraz zincir reaksiyonu (PCR) ve / veya bilgisayarlı tomografi (BT) ile doğrulanan COVİD-19 hastasını kaydettik. Hastalar, yükleme dozu olarak birincigün iki kez 400 mg HCQ ve ardından 4 gün daha günde 2x200 mg aldı. Bu hastaların klinik, laboratuvar ve BT sonuçları hastane veri sisteminden geriye dönük olarak tarandı ve kaydedildi. Bulgular: Çalışmaya alınan 441 hastanın yaş ortalaması 37,61 ± 13,40 yıl olup, % 52,38'i (n = 231) erkek,% 47,61'i (n = 210) kadındı. Hastaların ortalama hastanede kalış süresi 1,20 ± 2,48 gündü. Sadece 251 COVİD-19 hastasında (% 56,91(PCR) testi pozitifti ve hastanede yatan tüm hastaların 371 (% 84,12) bilgisayarlı tomografisi (BT) çekildi. Hastaların 219'unda (% 49,65) BT normaldi. Çalışmaya dahil edilen hastaların hiçbirinin yoğun bakım ünitesi tedavisine ihtiyaç duymadığı görüldü. Hidroksiklorokin tedavisine ek olarak hastaların sırasıyla% 14,6'sının (n = 67) ve% 0,4'ünün (n = 2) antikoagülan ve kortikosteroid tedavisi aldığı görüldü. Laboratuvar analizlerine göre PCR negatif olanların ortalama beyaz kan hücresi, C-reaktif protein (CRP), üre, D-Dimer değerleri pozitif olanlara göre anlamlı olarak yüksek bulundu (p: 0.000). Üç gün sonra, PCR negatif olanlarda sadece üre değerlerinin anlamlı yüksek (p: 0,001) kaldığı görüldü. Sonuç: Hastanede yatan ve HCQ tedavisi gören COVİD-19 hastalarımızın tamamında klinik ve laboratuvar olarak iyileştiği görüldü. Bu hastalarda herhangi bir yan etki gözlemlemedik.

THE EFFICACY OF HYDROXYCHLOROQUINE IN HOSPITALIZED COVID-19 POSITIVE PATIENTS

Introduction: In this study, as one of the reference hospitals in Turkey, we aimed to report our observationsrelated to the efficacy and safety of Hydroxychloroquine (HCQ) in the treatment of COVID-19 patients.Material and Methods: We enrolled 441 treatment-naive (between March 13 and June 15, 2020), hospitalizedCOVID-19 patients confirmed by polymerase chain reaction (PCR) and/or computerized tomography (CT). Theİzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi (Medical Journal of İzmir Hospital) 25 (2): 147-154, 2021148 İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi (Medical Journal of İzmir Hospital)patients have received HCQ 400 mg twice on day 1 as loading dose, and followed by 2x200 mg daily for 4additional days. Clinical, laboratory and CT results of these patients were extracted from the hospital data system,retrospectively.Results: Mean age of 441 patients included in the study was 37,61±13,40 year and 52.38% (n=231) were maleand 47.61% (n=210) were female. Mean length of hospitalization of patients was 1,20±2,48 day. PCR test waspositive only for 251 COVID-19 patients (56.91%) and CT of 371 (84.12%) patients was taken of all hospitalizedpatients. CT was normal in 219 (49.65%) of the patients. It was observed that none of the patients included in thestudy required intensive care unit treatment. In addition to hydroxychloroquine treatment, we also observed that14.6% (n=67) and 0.4% (n=2) of the patients received anticoagulant and corticosteroid treatment, respectively.According to laboratory analyses, the mean white blood cell, CRP, urea, D-Dimer values of the PCR negativeones were significantly higher than the positive ones (p: 0.000). After three days, it was seen that only urea valuesremained significantly high (p: 0.001) in PCR negative ones.Conclusion: We achieved clinical and laboratory improvement in all of our hospitalized COVID-19 patients whoreceived HCQ treatment. We did not observe any side effects in these patients.

PDF

___

1. Tyrrell DA, Almeida JD, Cunningham CH, Dowdle WR, Hofstad MS, McIntosh K, et al. Coronaviridae. Intervirology 1975; 5(1-2): 76–82.
2. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/ dg/speeches/detail/ who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19- 11- March- 2020.
3. https://covid19.saglik.gov.tr/Eklenti/39027/0/covid-19rehberieriskinhastatedavisipdf.pdf
4. Gonzalez-Dunia D, Cubitt B, de la Torre JC. Mechanism of Borna disease virus entry into cells. J Virol 1998; 72(1): 783–8.
5. Ros C, Burckhardt CJ, Kempf C. Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol 2002; 76(24): 12634–45.
6. Diaz-Griffero F, Hoschander SA, Brojatsch J. Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J Virol 2002; 76(24): 12866–76.
7. Bishop NE. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 1998; 41(6): 261–71.
8. Ferreira DF, Santo MP, Rebello MA, Rebello MC. Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells. J Med Microbiol 2000; 49(4): 313–8.
9. Harley CA, Dasgupta A, Wilson DW. Characterization of herpes simplex virus containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles. J Virol 2001; 75(3): 1236–51.
10. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271–80.
11. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; 75(7): 1667-70.
12. Yan Y, Zou Z, Sun Y, Li X, Xu KF , Wei Y et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013; 23(2): 300-2.
13. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2(8): 69.
14. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
15. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
16. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6(3): 16.
17. Chen Jun, Liu Danping, Liu Li, Liu Ping, Xu Qingnian, Xia Lu et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID -19). Journal Of Zhejiang University 2020; 49(2): 215-9.
18. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949.
19. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3